Dr. Christian Rohlff, Ph.D. is the Founder of Oxford BioTherapeutics Ltd and has been its Chief Executive Officer since 2004. Dr. Rohlff served as Chairman at Oxford BioTherapeutics Ltd until February 9, 2017 and serves as its Director. Dr. Rohlff joined Oxford GlycoSciences and served as Director of Proteome Research Collaborations in 2001. As manager of the Proteomics Division's commercial collaborations, he gained expertise in the implementation of clinical proteomics programs to identify novel therapeutic protein targets and protein biomarkers with many pharmaceutical companies and academic partners, including Pfizer, GSK, Bayer, Wyeth, Takeda, the Cystic Fibrosis Foundation, Oxford University and the FDA. Dr. Rohlff co-authored over 20 protein patents originating from these studies. Dr. Rohlff also a founding member on the board of the South East Health Technologies Alliance (SEHTA), whose mission it is to catalyse innovation and international competitiveness in south east England's health technologies sector. He received his Ph.D from the Department of Pharmacology at Georgetown University in 1994.

 Genetics, Clinical Proteomics